Welcome to our dedicated page for Coherus news (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus stock.
Coherus Oncology, Inc. reports commercial-stage oncology developments centered on LOQTORZI® (toripalimab-tpzi), an approved next-generation PD-1 inhibitor for recurrent or metastatic nasopharyngeal carcinoma. Company updates also cover its antibody immunotherapy pipeline, including tagmokitug, an anti-CCR8 cytolytic antibody, and casdozokitug, an IL-27 antagonistic antibody, across solid-tumor programs such as liver, prostate, head and neck, colorectal, gastric and esophageal cancers.
Recurring news includes financial results, LOQTORZI revenue commentary, clinical-development updates, strategic partnerships, investor-conference presentations, public common-stock offerings, debt reduction and other capital-structure actions tied to the company's transition from biosimilars to innovative oncology.
Coherus BioSciences (CHRS) will present at the BofA Securities 2020 Health Care Conference on May 14, 2020, at 1:00 p.m. ET. The presentation will be streamed live on their investor page. Coherus is a biosimilar leader focused on developing therapeutics for chronic diseases while enhancing patient access and reducing costs. The company markets UDENYCA® in the U.S. and is advancing several biosimilars, including CHS-1420, targeting Humira® and others. Visit https://investors.coherus.com for more details.